Skip to main content
. 2022 Oct;12(5):563–576. doi: 10.21037/cdt-22-172

Table 2. Cox regression analysis to evaluate the predictive effect of SXscore and standard assessment on the outcomes with adjustment for confounding factors.

Treatment All-cause death MACCE
HRadjusted (95% CI) P value HRadjusted (95% CI) P value
MT alone
   SXscore≥23 7.93 (0.86–73.3) 0.068 2.99 (0.20–45.80) 0.431
   LMMCAD 4.13 (0.96–17.7) 0.056 8.72 (1.73–44.10) 0.009
PCI
   SXscore≥23 4.83 (0.41–57.00) 0.211 3.16 (0.97–10.30) 0.055
   LMMCAD 3.65 (0.67–19.9) 0.134 1.28 (0.58–2.86) 0.541
CABG
   SXscore≥23 0.75 (0.08–7.22) 0.802 1.73 (0.46–6.51) 0.416
   LMMCAD 0.66 (0.02–18.6) 0.808 1.36 (0.33–5.56) 0.670
Total sample
   SXscore≥23 1.83 (0.52–6.39) 0.344 1.42 (0.97–2.08) 0.069
   LMMCAD 2.81 (1.17–6.74) 0.021 1.71 (0.94–3.13) 0.081

, adjusted for age, male, BMI, diabetes mellitus, hypertension, previous myocardial infarction, HDL-C, creatinine, LVEF, current smoking, and chest pain. , adjusted for therapeutic method, age, male, BMI, diabetes mellitus, hypertension, previous myocardial infarction, HDL-C, creatinine, LVEF, current smoking, and chest pain. MACCE, major adverse cardiac and cerebral events; MT, medical-therapy; SXscore, SYNTAX score; LMMCAD, left main or multivessel coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LVEF, left ventricular fraction ejection.